Placebo + Cisplatin + Carboplatin + Paclitaxel + Bevacizumab

This appears to be a combination therapy used in clinical trials for cancer treatment. The combination includes: 1. Placebo - an inactive substance used as a control in clinical trials 2. Cisplatin - a platinum-based chemotherapy drug 3. Carboplatin - another platinum-based chemotherapy drug 4. Paclitaxel - a taxane chemotherapy drug 5. Bevacizumab (Avastin) - a monoclonal antibody that targets vascular endothelial growth factor (VEGF) Bevacizumab is a key component of this combination. It works by inhibiting angiogenesis (the formation of new blood vessels) by blocking VEGF, thereby starving tumors of their blood supply. It's commonly used in combination with other chemotherapy agents for various cancer types. The search results indicate that bevacizumab is approved for use in combination with carboplatin and paclitaxel for certain cancers, including non-squamous non-small cell lung cancer. It's also used with paclitaxel and cisplatin for persistent, recurrent, or metastatic cervical cancer. This specific combination with a placebo component suggests it may be part of a clinical trial design where some patients receive the active treatment combination while others receive a placebo in place of one of the components, typically to evaluate the efficacy of a particular drug within the combination. The combination therapy would likely be administered intravenously, as bevacizumab is given as a drip into the bloodstream.